Researchers have recently identified a new form of regulated cell death called ferroptosis, which is now recognized as a programmed cell death mechanism. Unlike apoptosis, which is caspase-dependent, or necrosis, which is often uncontrolled, ferroptosis is driven by iron accumulation and lipid peroxidation². First described in 2012, ferroptosis has since emerged as a key player in various diseases, including cancer and neurodegeneration³.

This growing interest in ferroptosis stems from its unique biology and its potential to open new therapeutic avenues. Understanding how ferroptosis works and how it can be modulated may help us tackle some of the most challenging conditions in medicine.

What is ferroptosis in programmed cell death?

Ferroptosis is a form of regulated cell death that depends on iron and the accumulation of lipid-based reactive oxygen species (ROS). It is distinct from other forms of cell death in both morphology and mechanism. Ferroptosis represents a type of ferroptotic cell death and is classified as nonapoptotic cell death, setting it apart from apoptosis and necroptosis. Cells undergoing ferroptosis show shrunken mitochondria, increased membrane density, and reduced or absent cristae⁴.

At the molecular level, ferroptosis is triggered when the cell’s antioxidant defenses are overwhelmed. A key player in this process is glutathione peroxidase 4 (GPX4), an enzyme that reduces lipid hydroperoxides to non-toxic lipid alcohols. When GPX4 is inhibited or its cofactor glutathione is depleted, lipid peroxides accumulate, leading to oxidative damage and cell death⁵.

Another important component is system Xc⁻, a cystine/glutamate antiporter that imports cystine for glutathione synthesis. Blocking this system reduces glutathione levels, indirectly impairing GPX4 activity. Iron metabolism also plays a central role. Excess free iron catalyzes the formation of ROS through the Fenton reaction, amplifying lipid peroxidation⁶. Proper iron homeostasis is therefore critical in regulating ferroptosis and preventing excessive cell death. In addition, polyunsaturated fatty acids are key substrates for lipid peroxidation during ferroptosis, making their presence essential for executing this pathway.

These features make ferroptosis mechanistically unique and biologically significant. Unlike apoptosis, it does not involve DNA fragmentation or caspase activation. Instead, it is characterized by metabolic dysfunction and oxidative stress⁷.

Ferroptosis in cancer cells: a double-edged sword

Cancer cells often develop resistance to apoptosis, allowing them to survive under stress and evade therapy. Ferroptosis offers an alternative route to eliminate these cells. Many tumors, especially those with high metabolic activity, are vulnerable to ferroptosis due to their increased iron uptake and lipid synthesis⁸. As a result, ferroptosis is being actively explored in cancer therapy as a novel approach to target resistant cancer cells.

For example, pancreatic cancer and triple-negative breast cancer have shown sensitivity to ferroptosis-inducing agents in preclinical models. In glioblastoma, targeting ferroptosis pathways has been proposed as a strategy to overcome resistance to conventional therapies⁹. Additionally, colon cancer, lung cancer, and ovarian cancer are among other cancer types where the role of ferroptosis is under investigation for potential cancer treatment strategies¹⁰.

However, cancer cells can also develop mechanisms to resist ferroptosis. These include upregulating antioxidant systems, altering iron metabolism, or increasing expression of ferroptosis suppressors like FSP1. Understanding these resistance pathways is key to designing effective combination therapies¹¹.

Researchers are now exploring how to sensitize tumors to ferroptosis. This includes using small molecules like erastin and RSL3, which inhibit system Xc⁻ and GPX4, respectively¹². Combining these agents with chemotherapy or immunotherapy may enhance treatment outcomes.

Early detection and understanding of risk factors can guide timely interventions and improve cancer treatment outcomes.

Ferroptosis in neurodegenerative diseases: friend or foe?

Neurons are particularly vulnerable to oxidative stress due to their high metabolic rate and lipid-rich membranes. In neurodegenerative diseases, such as Alzheimer’s, Parkinson’s, amyotrophic lateral sclerosis (ALS), and Huntington’s disease, iron accumulation and lipid peroxidation are common features¹³.

These observations have led to the hypothesis that ferroptosis may contribute to neuronal loss in these conditions. For instance, elevated iron levels have been detected in the substantia nigra of Parkinson’s patients, and markers of lipid peroxidation are increased in Alzheimer’s brains¹⁴.

Targeting ferroptosis in the nervous system is complex. While inhibiting ferroptosis may protect neurons, it must be done without disrupting normal iron metabolism or antioxidant defenses. Moreover, the blood–brain barrier poses challenges for drug delivery.

Despite these hurdles, ferroptosis inhibitors such as ferrostatin-1 and liproxstatin-1 have shown neuroprotective effects in animal models^15-17. These findings suggest that modulating ferroptosis could be a promising strategy for slowing disease progression.

Therapeutic landscape and drug development

Several small molecules that modulate ferroptosis are under investigation¹⁸. These include:

• Erastin: inhibits system Xc⁻, reducing glutathione synthesis.
• RSL3: directly inhibits GPX4.
• Ferrostatins: prevent lipid peroxidation and protect against ferroptosis.
• Iron chelators: reduce free iron levels and limit ROS production.

Some of these compounds are in preclinical development, while others are being tested in early-phase clinical trials. The challenge lies in achieving selective targeting, inducing ferroptosis in cancer cells while sparing healthy tissues, or preventing it in neurons without impairing normal cell function.

Drug development in this space is still in its early stages, but the potential applications are broad. From oncology to neurology, ferroptosis modulation could complement existing therapies and address unmet medical needs.

Emerging technologies and research tools

Advances in CRISPR screening, single-cell omics, and live-cell imaging are accelerating ferroptosis research. These tools help identify new regulators, map cell-type-specific responses, and monitor lipid peroxidation in real time¹⁹.

Biomarkers for ferroptosis are also being explored. These include lipid peroxidation products, iron-related proteins, and gene expression signatures. Reliable biomarkers could aid in patient stratification and treatment monitoring¹⁹.

Artificial intelligence and computational biology are playing a growing role in predicting ferroptosis sensitivity and designing new compounds. By integrating multi-omics data, researchers can uncover hidden patterns and generate testable hypotheses²⁰.

Future directions and open questions

Despite rapid progress, many questions remain. Can ferroptosis be selectively induced in tumors without harming normal cells? How does the tumor microenvironment influence ferroptosis sensitivity? What are the long-term effects of ferroptosis modulation in chronic diseases?

Answering these questions will require interdisciplinary collaboration across oncology, neurology, pharmacology, and systems biology. As our understanding deepens, ferroptosis may become a valuable tool in the therapeutic arsenal.

Ferroptosis represents a new dimension in cell death biology. Its role in cancer and neurodegeneration is complex but promising. By continuing to explore its mechanisms and therapeutic potential, we may uncover new ways to treat diseases that have long resisted conventional approaches.

References

1. Park, W.  et al.  Diversity and complexity of cell death: a historical review.  Exp. Mol. Med.  55, 1573–1594 (2023).
2. Tang, D., Chen, X., Kang, R.  et al.  Ferroptosis: molecular mechanisms and health implications.  Cell Res.  31, 107–125 (2021).
3. Dixon, S. J.  et al.  Ferroptosis: an iron-dependent form of nonapoptotic cell death.  Cell  149, 1060–1072 (2012).
4. Battaglia, A. M.  et al.  Ferroptosis and cancer: mitochondria meet the "Iron Maiden" cell death.  Cells  9, 1505 (2020).
5. Yu, Y., Yan, Y., Niu, F.  et al.  Ferroptosis: a cell death connecting oxidative stress, inflammation and cardiovascular diseases.  Cell Death Discov.  7, 193 (2021).
6. Li, F.-J.  et al.  System Xc⁻/GSH/GPX4 axis: an important antioxidant system for the ferroptosis in drug-resistant solid tumor therapy.  Front. Pharmacol.  13, 910292 (2022).
7. Sun, J.  et al.  CHAC1: a master regulator of oxidative stress and ferroptosis in human diseases and cancers.  Front. Cell Dev. Biol.  12, 1458716 (2024).
8. Zhou, Q., Meng, Y., Li, D.  et al.  Ferroptosis in cancer: from molecular mechanisms to therapeutic strategies.  Signal Transduct. Target Ther.  9, 55 (2024).
9. Wang, Y.  et al.  Mechanism of ferroptosis resistance in cancer cells.  Cancer Drug Resist.  7, 47 (2024).
10. Wang, W., Li, T. & Wu, K. Cell death in tumor microenvironment: an insight for exploiting novel therapeutic approaches.  Cell Death Discov.  11, 93 (2025).
11. Lei, G.  et al.  Targeting ferroptosis as a vulnerability in cancer.  Nat. Rev. Cancer  22, 381–396 (2022).
12. Wang, L.  et al.  Ferroptosis: an emerging therapeutic opportunity for cancer.  Genes Dis.  9, 334–346 (2020).
13. Sienes Bailo, P.  et al.  The role of oxidative stress in neurodegenerative diseases and potential antioxidant therapies.  Adv. Lab. Med.  3, 342–360 (2022).
14. Fei, Y. & Ding, Y. The role of ferroptosis in neurodegenerative diseases.  Front. Cell. Neurosci.  18, 1475934 (2024).
15. Scarpellini, C.  et al.  Beyond ferrostatin-1: a comprehensive review of ferroptosis inhibitors.  Trends Pharmacol. Sci.  44, 902–916 (2023).
16. Tan, Q.  et al.  Identifying eleven new ferroptosis inhibitors as neuroprotective agents from FDA-approved drugs.  Bioorg. Chem.  146, 107261 (2024).
17. Li, Y.  et al.  The ferroptosis inhibitor liproxstatin-1 ameliorates LPS-induced cognitive impairment in mice.  Nutrients  14, 4599 (2022).
18. Sun, S., Shen, J., Jiang, J.  et al.  Targeting ferroptosis opens new avenues for the development of novel therapeutics.  Signal Transduct. Target Ther.  8, 372 (2023).
19. Menon, A. V.  et al.  Unraveling the future of genomics: CRISPR, single-cell omics, and the applications in cancer and immunology.  Front. Genome Ed.  7, 1565387 (2025).
20. Chen, X.  et al.  Characteristics and biomarkers of ferroptosis.  Front. Cell Dev. Biol.  9, 637162 (2021).
21. Fernández-Acosta, R., Vintea, I., Koeken, I.  et al.  Harnessing ferroptosis for precision oncology: challenges and prospects.  BMC Biol.  23, 57 (2025).